News Feed

MPN News

MPN rss feedThe MPN News feed provides frequent updates on the latest happenings in the MPN World. Fresh content, with brief summary is automatically updated frequently from reliable sources.  Just click on the red hyperlink to pull up the complete news item.

Make PV Reporter your “starting point” for all MPN related news.

The investigational agent pacritinib (CTI BioPharma) holds promise as a treatment option for patients with myelofibrosis and baseline thrombocytopenia, and previous concerns that led to a hold on clinical trials have now been dispelled. In a pivotal trial, PERSIST-2, pacritinib was significantly more effective than the best available therapy, including ruxolitinib [...]
Thu, Mar 15, 2018, Continue reading at the source
People with myelofibrosis who are currently receiving ruxolitinib therapy may be eligible for a new phase II clinical trial led by Dr. Ellen Ritchie. Navitoclax is an investigational agent that inhibits a family of BCL proteins. These proteins block some of the enzymes that keep cancer cells from dying and by [...]
Wed, Mar 14, 2018, Continue reading at the source
View Dr. Mesa's explanation of MPNs in Spanish Ver la explicación del Dr. mesa de MPN en Español To view website in Spanish click the language option in the upper right corner of the website Para ver el sitio web en Español Haga clic en la opción de idioma en la esquina superior [...]
Wed, Mar 14, 2018, Continue reading at the source
Metformin demonstrates antileukemic activity and may have clinical implications for the treatment of myeloproliferative neoplasms (MPN) in combination with ruxolitinib, according to a study published in Cell Death & Disease. The JAK1/2 inhibitor ruxolitinib demonstrates clinical activity among patients with MPN (eg, essential thrombocythemia, primary myelofibrosis, polycythemia vera), but rarely produces [...]
Fri, Mar 09, 2018, Continue reading at the source
Patients with MPNs have increased inflammatory cytokines, which contribute to symptoms such as fatigue, night sweats and bone pain, as well as low cholesterol and weight loss related to nutritional deficiencies. BY Katie Kosko PUBLISHED March 05, 2018 DIET AND SUPPLEMENT USE can help alleviate some of the symptom burden experienced by patients [...]
Thu, Mar 08, 2018, Continue reading at the source
MPN Booklet 2018 The post MPN Advocacy & Education International Booklet (2018) appeared first on MPN Advocacy & Education International. [...]
Mon, Mar 05, 2018, Continue reading at the source
AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE Researchers have discovered how some of the blood cancers known as myeloproliferative neoplasms (MPNs) evade the immune system. Their findings reveal that a subset of MPNs might be susceptible to treatment with immune checkpoint inhibitors that specifically target the PD-1/PD-L1 pathway (a signaling [...]
Thu, Feb 22, 2018, Continue reading at the source
clinical trial in myelofibrosis
Imago BioSciences, a clinical-stage pharmaceutical company developing novel therapies for hematological and inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted their Investigational New Drug (IND) application providing clearance to proceed with the clinical development of IMG-7289 in the U.S. The IND supports the company's ongoing [...]
Thu, Feb 01, 2018, Continue reading at the source
Website Temporarily Unavailable
Celgene Corporation (NASDAQ:CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in [...]
Sun, Jan 07, 2018, Continue reading at the source
Nutlin Antagonist Shows Activity in Polycythemia Vera
The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera (PV). Data from a 2-part single-institution, open-label, dose-escalation phase I study showed a 75% overall response rate when idasanutlin was given as a monotherapy or in combination [...]
Tue, Dec 26, 2017, Continue reading at the source
February 29th is Rare Disease Day: 4 Reasons You Should Care Even though MPN patients who have a rare disease many may have never heard of "Rare Disease Day" and know next to nothing about the impact rare disorders have on society. Rare diseases play a larger role in public [...]
Mon, Feb 29, 2016, Continue reading at the source
It's World Cancer Day There has been, from time to time, a question about whether myeloproliferative neoplasms are cancers. Let's be clear, they are. But don't take our word for it. Cancer Support Community defines Myeloproliferative Neoplasms (MPNs) as types of blood cancers that overproduce blood cells in the bone [...]
Mon, Feb 01, 2016, Continue reading at the source
For the past several months we've kept you informed and taking action on Medicare's pending decision of whether to provide coverage for people with myelofibrosis seeking a stem cell transplant. Currently there is no official ruling from Medicare on whether this treatment is covered, leaving many patients to risk paying [...]
Tue, Jan 12, 2016, Continue reading at the source
Each year for the past three years, Cure Magazine and Incyte Corporation have recognized efforts within the MPN community with their MPN Hero award. The two categories are commitment to the community or individual. Past winners have included Ruben Mesa, Zhenya Senyak, Joyce Niblack, Richard Silver, and many more. We [...]
Sun, Dec 27, 2015, Continue reading at the source
According to a paper published in Nature Medicine, the drug MLN8237 (or Alisertib) has reduced tumor cells, blood counts and fibrosis in mouse models of myelofibrosis. Reports John Crispino, PhD, "This new paper shows that Alisertib has an anti-tumor effect in samples of myelofibrosis, similar to what we saw in [...]
Tue, Dec 01, 2015, Continue reading at the source

error: Content is protected !!